市場調査レポート
商品コード
1234283

びまん性大細胞型B細胞リンパ腫(DLBCL)治療薬の世界市場 2023-2027

Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 166 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
びまん性大細胞型B細胞リンパ腫(DLBCL)治療薬の世界市場 2023-2027
出版日: 2023年02月21日
発行: TechNavio
ページ情報: 英文 166 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、びまん性大細胞型B細胞リンパ腫(DLBCL)治療薬の市場規模は、2022年から2027年の間に20億6,188万米ドル増加する見込みで、予測期間中のCAGRは7.96%で成長すると予測しています。

当レポートでは、びまん性大細胞型B細胞リンパ腫(DLBCL)治療薬市場について、全体的な分析、市場規模と予測、動向、成長促進要因・課題、さらに約25のベンダーを網羅したベンダー分析を行っています。

現在の市場シナリオ、最新動向と促進要因、市場全体の環境に関する最新の分析を提供しています。市場は、高齢者人口の増加、DLBCLの発症率の増加、再発または難治性のDLBCL患者に対する治療薬の承認の増加によって牽引されています。

本調査では、今後数年間におけるびまん性大細胞型B細胞リンパ腫(DLBCL)治療薬市場の成長を促す主な理由の一つとして、技術的進歩を挙げています。また、患者支援プログラムの増加や戦略的提携は、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界のびまん性大細胞型B細胞リンパ腫(DLBCL)治療薬市場2017~2021年
  • アプリケーションセグメント分析2017-2021
  • 製品セグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 アプリケーション別市場セグメンテーション

  • マーケット・セグメント
  • 用途別比較
  • 病院薬局 - 市場規模と予測 2022-2027
  • 小売薬局 - 市場規模と予測 2022-2027
  • オンライン薬局 - 市場規模と予測 2022-2027
  • その他 - 市場規模と予測 2022-2027
  • アプリケーション別の市場機会

第7章 製品別の市場セグメンテーション

  • マーケット・セグメント
  • 製品別比較
  • 低分子 - 市場規模と予測 2022-2027
  • 生物製剤 - 市場規模と予測 2022-2027
  • 製品別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • カナダ - 市場規模と予測 2022-2027
  • 中国 - 市場規模と予測 2022-2027
  • 地域別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • BeiGene Ltd.
  • Bristol Myers Squibb Co.
  • Celltrion Healthcare Co. Ltd.
  • CTI BioPharma Corp.
  • Erytech Pharma SA
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market by Geography
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Application
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Application - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Application - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Application
  • Exhibits33: Data Table on Comparison by Application
  • Exhibits34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibits44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibits46: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits48: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits49: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits50: Market opportunity by Application ($ million)
  • Exhibits51: Data Table on Market opportunity by Application ($ million)
  • Exhibits52: Chart on Product - Market share 2022-2027 (%)
  • Exhibits53: Data Table on Product - Market share 2022-2027 (%)
  • Exhibits54: Chart on Comparison by Product
  • Exhibits55: Data Table on Comparison by Product
  • Exhibits56: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
  • Exhibits58: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)
  • Exhibits60: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibits61: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibits62: Chart on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibits63: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibits64: Market opportunity by Product ($ million)
  • Exhibits65: Data Table on Market opportunity by Product ($ million)
  • Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits67: Chart on Market share by geography 2022-2027 (%)
  • Exhibits68: Data Table on Market share by geography 2022-2027 (%)
  • Exhibits69: Chart on Geographic comparison
  • Exhibits70: Data Table on Geographic comparison
  • Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits101: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits103: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits104: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits105: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits106: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits107: Market opportunity by geography ($ million)
  • Exhibits108: Data Tables on Market opportunity by geography ($ million)
  • Exhibits109: Impact of drivers and challenges in 2022 and 2027
  • Exhibits110: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits111: Overview on factors of disruption
  • Exhibits112: Impact of key risks on business
  • Exhibits113: Vendors covered
  • Exhibits114: Matrix on vendor position and classification
  • Exhibits115: AbbVie Inc. - Overview
  • Exhibits116: AbbVie Inc. - Product / Service
  • Exhibits117: AbbVie Inc. - Key news
  • Exhibits118: AbbVie Inc. - Key offerings
  • Exhibits119: Amgen Inc. - Overview
  • Exhibits120: Amgen Inc. - Product / Service
  • Exhibits121: Amgen Inc. - Key offerings
  • Exhibits122: Bayer AG - Overview
  • Exhibits123: Bayer AG - Business segments
  • Exhibits124: Bayer AG - Key news
  • Exhibits125: Bayer AG - Key offerings
  • Exhibits126: Bayer AG - Segment focus
  • Exhibits127: BeiGene Ltd. - Overview
  • Exhibits128: BeiGene Ltd. - Business segments
  • Exhibits129: BeiGene Ltd. - Key offerings
  • Exhibits130: BeiGene Ltd. - Segment focus
  • Exhibits131: Bristol Myers Squibb Co. - Overview
  • Exhibits132: Bristol Myers Squibb Co. - Product / Service
  • Exhibits133: Bristol Myers Squibb Co. - Key news
  • Exhibits134: Bristol Myers Squibb Co. - Key offerings
  • Exhibits135: Celltrion Healthcare Co. Ltd. - Overview
  • Exhibits136: Celltrion Healthcare Co. Ltd. - Product / Service
  • Exhibits137: Celltrion Healthcare Co. Ltd. - Key offerings
  • Exhibits138: CTI BioPharma Corp. - Overview
  • Exhibits139: CTI BioPharma Corp. - Product / Service
  • Exhibits140: CTI BioPharma Corp. - Key offerings
  • Exhibits141: Erytech Pharma SA - Overview
  • Exhibits142: Erytech Pharma SA - Product / Service
  • Exhibits143: Erytech Pharma SA - Key offerings
  • Exhibits144: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits145: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits146: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits147: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits148: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits149: GlaxoSmithKline Plc - Overview
  • Exhibits150: GlaxoSmithKline Plc - Business segments
  • Exhibits151: GlaxoSmithKline Plc - Key offerings
  • Exhibits152: GlaxoSmithKline Plc - Segment focus
  • Exhibits153: Johnson and Johnson - Overview
  • Exhibits154: Johnson and Johnson - Business segments
  • Exhibits155: Johnson and Johnson - Key news
  • Exhibits156: Johnson and Johnson - Key offerings
  • Exhibits157: Johnson and Johnson - Segment focus
  • Exhibits158: Merck and Co. Inc. - Overview
  • Exhibits159: Merck and Co. Inc. - Business segments
  • Exhibits160: Merck and Co. Inc. - Key news
  • Exhibits161: Merck and Co. Inc. - Key offerings
  • Exhibits162: Merck and Co. Inc. - Segment focus
  • Exhibits163: Novartis AG - Overview
  • Exhibits164: Novartis AG - Business segments
  • Exhibits165: Novartis AG - Key offerings
  • Exhibits166: Novartis AG - Segment focus
  • Exhibits167: Pfizer Inc. - Overview
  • Exhibits168: Pfizer Inc. - Product / Service
  • Exhibits169: Pfizer Inc. - Key news
  • Exhibits170: Pfizer Inc. - Key offerings
  • Exhibits171: Spectrum Pharmaceuticals Inc. - Overview
  • Exhibits172: Spectrum Pharmaceuticals Inc. - Product / Service
  • Exhibits173: Spectrum Pharmaceuticals Inc. - Key offerings
  • Exhibits174: Inclusions checklist
  • Exhibits175: Exclusions checklist
  • Exhibits176: Currency conversion rates for US$
  • Exhibits177: Research methodology
  • Exhibits178: Validation techniques employed for market sizing
  • Exhibits179: Information sources
  • Exhibits180: List of abbreviations
目次
Product Code: IRTNTR73132

Technavio has been monitoring the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market and is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the forecast period. Our report on the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of DLBCL, and increasing approval of therapeutics for patients with relapsed or refractory DLBCL.

Technavio's diffuse large B-Cell Lymphoma (DLBCL) therapeutics market is segmented as below:

By Application

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy
  • Others

By Product

  • Small molecules
  • Biologics

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies technological advances as one of the prime reasons driving the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market covers the following areas:

  • Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market sizing
  • Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market forecast
  • Diffuse large B-Cell Lymphoma (DLBCL) therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diffuse large B-Cell Lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global diffuse large B-Cell lymphoma (DLBCL) therapeutics market 2017 - 2021 ($ million)
  • 4.2 Application Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
  • 4.3 Product Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

  • 6.1 Market segments
  • Exhibit 30: Chart on Application - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
  • 6.2 Comparison by Application
  • Exhibit 32: Chart on Comparison by Application
  • Exhibit 33: Data Table on Comparison by Application
  • 6.3 Hospital pharmacy - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%)
  • 6.4 Retail pharmacy - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%)
  • 6.5 Online pharmacy - Market size and forecast 2022-2027
  • Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%)
  • Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%)
  • 6.6 Others - Market size and forecast 2022-2027
  • Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 6.7 Market opportunity by Application
  • Exhibit 50: Market opportunity by Application ($ million)
  • Exhibit 51: Data Table on Market opportunity by Application ($ million)

7 Market Segmentation by Product

  • 7.1 Market segments
  • Exhibit 52: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 53: Data Table on Product - Market share 2022-2027 (%)
  • 7.2 Comparison by Product
  • Exhibit 54: Chart on Comparison by Product
  • Exhibit 55: Data Table on Comparison by Product
  • 7.3 Small molecules - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Small molecules - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Small molecules - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Small molecules - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Small molecules - Year-over-year growth 2022-2027 (%)
  • 7.4 Biologics - Market size and forecast 2022-2027
  • Exhibit 60: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 61: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Chart on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibit 63: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Product
  • Exhibit 64: Market opportunity by Product ($ million)
  • Exhibit 65: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
  • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 69: Chart on Geographic comparison
  • Exhibit 70: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Germany - Market size and forecast 2022-2027
  • Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.9 UK - Market size and forecast 2022-2027
  • Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.10 Canada - Market size and forecast 2022-2027
  • Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.11 China - Market size and forecast 2022-2027
  • Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 107: Market opportunity by geography ($ million)
  • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 111: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 112: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 113: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 114: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 115: AbbVie Inc. - Overview
  • Exhibit 116: AbbVie Inc. - Product / Service
  • Exhibit 117: AbbVie Inc. - Key news
  • Exhibit 118: AbbVie Inc. - Key offerings
  • 12.4 Amgen Inc.
  • Exhibit 119: Amgen Inc. - Overview
  • Exhibit 120: Amgen Inc. - Product / Service
  • Exhibit 121: Amgen Inc. - Key offerings
  • 12.5 Bayer AG
  • Exhibit 122: Bayer AG - Overview
  • Exhibit 123: Bayer AG - Business segments
  • Exhibit 124: Bayer AG - Key news
  • Exhibit 125: Bayer AG - Key offerings
  • Exhibit 126: Bayer AG - Segment focus
  • 12.6 BeiGene Ltd.
  • Exhibit 127: BeiGene Ltd. - Overview
  • Exhibit 128: BeiGene Ltd. - Business segments
  • Exhibit 129: BeiGene Ltd. - Key offerings
  • Exhibit 130: BeiGene Ltd. - Segment focus
  • 12.7 Bristol Myers Squibb Co.
  • Exhibit 131: Bristol Myers Squibb Co. - Overview
  • Exhibit 132: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 133: Bristol Myers Squibb Co. - Key news
  • Exhibit 134: Bristol Myers Squibb Co. - Key offerings
  • 12.8 Celltrion Healthcare Co. Ltd.
  • Exhibit 135: Celltrion Healthcare Co. Ltd. - Overview
  • Exhibit 136: Celltrion Healthcare Co. Ltd. - Product / Service
  • Exhibit 137: Celltrion Healthcare Co. Ltd. - Key offerings
  • 12.9 CTI BioPharma Corp.
  • Exhibit 138: CTI BioPharma Corp. - Overview
  • Exhibit 139: CTI BioPharma Corp. - Product / Service
  • Exhibit 140: CTI BioPharma Corp. - Key offerings
  • 12.10 Erytech Pharma SA
  • Exhibit 141: Erytech Pharma SA - Overview
  • Exhibit 142: Erytech Pharma SA - Product / Service
  • Exhibit 143: Erytech Pharma SA - Key offerings
  • 12.11 F. Hoffmann La Roche Ltd.
  • Exhibit 144: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 145: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 146: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 147: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 148: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.12 GlaxoSmithKline Plc
  • Exhibit 149: GlaxoSmithKline Plc - Overview
  • Exhibit 150: GlaxoSmithKline Plc - Business segments
  • Exhibit 151: GlaxoSmithKline Plc - Key offerings
  • Exhibit 152: GlaxoSmithKline Plc - Segment focus
  • 12.13 Johnson and Johnson
  • Exhibit 153: Johnson and Johnson - Overview
  • Exhibit 154: Johnson and Johnson - Business segments
  • Exhibit 155: Johnson and Johnson - Key news
  • Exhibit 156: Johnson and Johnson - Key offerings
  • Exhibit 157: Johnson and Johnson - Segment focus
  • 12.14 Merck and Co. Inc.
  • Exhibit 158: Merck and Co. Inc. - Overview
  • Exhibit 159: Merck and Co. Inc. - Business segments
  • Exhibit 160: Merck and Co. Inc. - Key news
  • Exhibit 161: Merck and Co. Inc. - Key offerings
  • Exhibit 162: Merck and Co. Inc. - Segment focus
  • 12.15 Novartis AG
  • Exhibit 163: Novartis AG - Overview
  • Exhibit 164: Novartis AG - Business segments
  • Exhibit 165: Novartis AG - Key offerings
  • Exhibit 166: Novartis AG - Segment focus
  • 12.16 Pfizer Inc.
  • Exhibit 167: Pfizer Inc. - Overview
  • Exhibit 168: Pfizer Inc. - Product / Service
  • Exhibit 169: Pfizer Inc. - Key news
  • Exhibit 170: Pfizer Inc. - Key offerings
  • 12.17 Spectrum Pharmaceuticals Inc.
  • Exhibit 171: Spectrum Pharmaceuticals Inc. - Overview
  • Exhibit 172: Spectrum Pharmaceuticals Inc. - Product / Service
  • Exhibit 173: Spectrum Pharmaceuticals Inc. - Key offerings

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 174: Inclusions checklist
  • Exhibit 175: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 176: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 177: Research methodology
  • Exhibit 178: Validation techniques employed for market sizing
  • Exhibit 179: Information sources
  • 13.5 List of abbreviations
  • Exhibit 180: List of abbreviations